# Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

> **NCT06838286** · — · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 10000 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** Thiazolidinedione
- **DRUG:** DPP-4 inhibitor

## Key facts

- **NCT ID:** NCT06838286
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 10000 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838286, "Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06838286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*